DOCSLIB.ORG

Consumer Directed Healthcare (CDH) Preventive Medicine List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Consumer Directed Healthcare (CDH) Preventive Medicine List Consumer Directed Healthcare (CDH) Preventive Medicine List This list provides examples of commonly prescribed preventive medicines. It is not an all-inclusive list; only examples of medicines in each category are listed. This list does not indicate coverage. Please check with your plan administrator and/or benefit information materials if you have questions on coverage. Your cost share will be determined by your plan’s drug coverage and formulary plan. Coverage prior to the deductible being met may not be provided for every dosage form of a listed medicine. Please note: When feasible, brand names are shown in capitals in each category. If generic is available, it is listed in lowercase next to the brand name. If only generics are available (for example, brands are no longer available), they will only be listed in lowercase. BONE DISEASE AND FRACTURES HEART DISEASE AND STROKE OTHER AGENTS ACTONEL, ATELVIA (risedronate) COLESTID (colestipol) BLOOD THINNER MEDICINES BONIVA (ibandronate) ezetimibe DUAVEE aspirin, 81 mg & 325 mg* ezetimibe/simvastatin EVISTA (raloxifene) AGGRENOX LOPID (gemfibrozil) FOSAMAX, FOSAMAX D, BINOSTO (aspirin/dipyridamole ER) NIASPAN (niacin) (alendronate) BRILINTA PREVALITE, QUESTRAN RECLAST (zoledronic acid) clopidogrel (cholestyramine) COUMADIN (warfarin) REPATHA CAVITIES DURLAZA ER TRICOR, ANTARA (fenofibrate) CLINPRO EFFIENT TRILIPIX DR (fenofibric acid) GEL-KAM ELIQUIS WELCHOL PHOS-FLUR PERSANTINE (dipyridamole) PREVIDENT PRADAXA HIGH BLOOD PRESSURE Sodium fluoride rinse, gel, SAVAYSA ACE INHIBITORS cream, paste, tabs and drops ticlopidine Stannous fluoride rinse and gel XARELTO ACCUPRIL (quinapril) ZONTIVITY ACEON (perindopril) COLONOSCOPY PREPARATION* ALTACE (ramipril) COLYTE, GOLYTELY, NULYTELY CHOLESTEROL LOWERING captopril (polyethylene glycol) MEDICINES fosinopril MOVIPREP LOTENSIN (benazepril) HMG-COA REDUCTASE OSMOPREP MAVIK (trandolapril) INHIBITORS* PREPOPIK moexipril SUPREP ALTOPREV PRINIVIL, ZESTRIL (lisinopril) CRESTOR (rosuvastatin) VASOTEC (enalapril) LESCOL (fluvastatin) LIPITOR (atorvastatin) ACE INHIBITORS/ DIURETIC LIVALO COMBINATIONS lovastatin ACCURETIC (quinapril/HCTZ) PRAVACHOL (pravastatin) captopril/HCTZ ZOCOR (simvastatin) fosinopril/HCTZ LOTENSIN HCT (benazepril/HCTZ) moexipril/HCTZ DL47415K (over, please) CDH Preventive Medicine List VASERETIC (enalapril/HCTZ) CALCIUM CHANNEL BLOCKERS OBESITY ZESTORETIC (lisinopril/HCTZ) ADALAT CC, PROCARDIA XL ADIPEX-P (phentermine) LOTENSIN HCT (benazepril/HCTZ) (nifedipine) BELVIQ ANGIOTENSIN II RECEPTOR CALAN, VERELAN (verapamil) BELVIQ XR ANTAGONISTS CARDENE (nicardipine) CONTRAVE CARDIZEM LA, TIAZAC ER diethylpropion AVAPRO (irbesartan) (diltiazem) REGIMEX (benzphetamine) candesartan felodipine ER LOMAIRA COZAAR (losartan) isradapine phendimetrazine DIOVAN (valsartan) NORVASC (amlodipine) SAXENDA EDARBI SULAR ER (nisoldipine) XENICAL MICARDIS (telmisartan) olmesartan DIURETICS SMOKING-CESSATION* ANGIOTENSIN II RECEPTOR chlorothiazide CHANTIX ANTAGONISTS/ DIURETIC chlorthalidone NICOTROL COMBINATIONS hydrochlorothiazide NICODERM CQ indapamide candesartan/HCTZ Nicotine gum, lozenges and metolazone AVALIDE (irbesartan/HCTZ) patches DIOVAN HCT (valsartan/HCTZ) OTHER HIGH BLOOD PRESSURE ZYBAN (bupropion SR 150mg) EDARBYCLOR MEDICINE COMBINATIONS IMMUNIZATION:* HYZAAR (losartan/HCTZ) amlodipine/olmesartan Antrax, BCG, Cholera, Diphtheria, MICARDIS HCT (telmisartan/HCTZ) amlodipine/olmesartan/HCTZ Haemophilus Influenza B, olmesartan/HCTZ BYVALSON Hepatitis A and B, Human BETA BLOCKERS CADUET (amlodipine/atorvastatin) Papillomavirus, Influenza, EXFORGE (amlodipine/valsartan) acebutolol Japanese Encephalitis, Measles, EXFORGE HCT betaxolol Meningococcal, Mumps, Pertussis, (amlodipine/valsartan/HCTZ) BYSTOLIC Pneumococcal, Poliovirus, Rabies, LOTREL (amlodipine/benazepril) CORGARD (nadolol) Rotavirus, Rubella, Tetanus, PRESTALIA INNOPRAN XL (propranolol) Typhoid, Varicella, Yellow Fever, TARKA (trandolapril/verapamil) TENORMIN (atenolol) Zoster TWYNSTA TOPROL XL, LOPRESSOR (amlodipine/telmisartan) VITAMINS OR MINERALS (metoprolol) ZEBETA (bisoprolol) RESPIRATORY SYNCYTIAL VIRUS folic acid* Prenatal vitamins BETA BLOCKER/DIURETIC SYNAGIS Pediatric multivitamins with COMBINATIONS MALARIA fluoride* CORZIDE chloroquine (nadolol/bendroflumethiazide) mefloquine LOPRESSOR HCT PRIMAQUINE (metoprolol/HCTZ) MALARONE propranolol/HCTZ (atovaquone/ proguanil) TENORETIC (atenolol/chlorthalidone) ZIAC (bisoprolol/HCTZ) DL47415K CDH Preventive Medicine List *Please note that some of these medicines are also subject to the Affordable Care Act (ACA) and may be covered by your plan at 100%. Express Scripts manages your prescription benefit for your employer, plan sponsor, or health plan. For specific questions on coverage, please call the phone number on your member ID card or visit our website express-scripts.com. FPO All rights in the product names of all third-party products appearing here, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. DL47415K 8.17 DL47415K.
Load more

Recommended publications
  • Pharmacokinetic Interactions Between Herbal Medicines and Drugs: Their Mechanisms and Clinical Relevance
    life Review Pharmacokinetic Interactions between Herbal Medicines and Drugs: Their Mechanisms and Clinical Relevance Laura Rombolà 1 , Damiana Scuteri 1,2 , Straface Marilisa 1, Chizuko Watanabe 3, Luigi Antonio Morrone 1, Giacinto Bagetta 1,2,* and Maria Tiziana Corasaniti 4 1 Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, Section of Preclinical and Translational Pharmacology, University of Calabria, 87036 Rende, Italy; [email protected] (L.R.); [email protected] (D.S.); [email protected] (S.M.); [email protected] (L.A.M.) 2 Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy 3 Department of Physiology and Anatomy, Tohoku Pharmaceutical University, 981-8558 Sendai, Japan; [email protected] 4 School of Hospital Pharmacy, University “Magna Graecia” of Catanzaro and Department of Health Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0984-493462 Received: 28 May 2020; Accepted: 30 June 2020; Published: 4 July 2020 Abstract: The therapeutic efficacy of a drug or its unexpected unwanted side effects may depend on the concurrent use of a medicinal plant. In particular, constituents in the medicinal plant extracts may influence drug bioavailability, metabolism and half-life, leading to drug toxicity or failure to obtain a therapeutic response. This narrative review focuses on clinical studies improving knowledge on the ability of selected herbal medicines to influence the pharmacokinetics of co-administered drugs. Moreover, in vitro studies are useful to anticipate potential herbal medicine-drug interactions.
    [Show full text]
  • Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies
    Chinese Journal of Physiology 61(1): 1-13, 2018 1 DOI: 10.4077/CJP.2018.BAG516 Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies Tzu-Tung Chang, Chia-Jung Yang, Yu-Chi Lee, and Sheng-Nan Wu Department of Physiology, National Cheng Kung University Medical College, Tainan 70101, Taiwan, Republic of China Abstract Telmisartan (Tel) is recognized as a non-peptide blocker of AT1R. Whether this agent has any direct effects on ion currents remains unexplored. In whole-cell current recordings, addition of Tel + increased the peak amplitude of voltage-gated Na (NaV) current (INa) accompanied by the increased time constant of INa inactivation in differentiated NSC-34 motor neuron-like cells. Tel-stimulated INa in these cells is unlinked to either blockade of AT1R or activation of peroxisome proliferator-activated receptor gamma (PPAR-γ). In order to explore how this compound affects the amplitude and kinetics of INa in neurons, a Hodgkin-Huxley-based (HH-based) model designed to mimic effect of Tel on the functional activities of neurons was computationally created in this study. In this framework, the parameter for h inactivation gating variable, which was changed in a stepwise fashion, was implemented + + to predict changes in membrane potentials (V) as a function of maximal Na (GNa), K conductance (GK), or both. As inactivation time course of INa was increased, the bifurcation point of V versus GNa became lower, and the range between subcritical and supercritical values at the bifurcation of V versus GK correspondingly became larger.
    [Show full text]
  • The Differential Effects of Statins on the Metastatic Behaviour of Prostate Cancer
    British Journal of Cancer (2012) 106, 1689–1696 & 2012 Cancer Research UK All rights reserved 0007 – 0920/12 www.bjcancer.com The differential effects of statins on the metastatic behaviour of prostate cancer *,1 1 1 2,3 2,3 2,4 1,2,4 M Brown , C Hart , T Tawadros , V Ramani , V Sangar , M Lau and N Clarke 1 Genito Urinary Cancer Research Group, University of Manchester, Paterson Institute for Cancer Research, Manchester Academic Health Science Centre, 2 The Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK; Department of Urology, The Christie NHS Foundation 3 Trust, Wilmslow Road, Manchester M20 4BX, UK; Department of Urology, University Hospital of South Manchester NHS Trust, Manchester M23 9LT, 4 UK; Department of Urology, Salford Royal NHS Foundation Trust, Stott Lane, Manchester M6 8HD, UK BACKGROUND: Although statins do not affect the incidence of prostate cancer (CaP), usage reduces the risk of clinical progression and mortality. Although statins are known to downregulate the mevalonate pathway, the mechanism by which statins reduce CaP progression is unknown. METHODS: Bone marrow stroma (BMS) was isolated with ethical approval from consenting patients undergoing surgery for non- malignant disease. PC-3 binding, invasion and colony formation within BMS was assessed by standardised in vitro co-culture assays in the presence of different statins. RESULTS: Statins act directly on PC-3 cells with atorvastatin, mevastatin, simvastatin (1 mM) and rosuvastatin (5 mM), but not pravastatin, significantly reducing invasion towards BMS by an average of 66.68% (range 53.93–77.04%; Po0.05) and significantly reducing both 2 2 number (76.2±8.29 vs 122.9±2.48; P ¼ 0.0055) and size (0.2±0.0058 mm vs 0.27±0.012 mm ; P ¼ 0.0019) of colonies formed within BMS.
    [Show full text]
  • What Precautions Should We Use with Statins for Women of Childbearing
    CLINICAL INQUIRIES What precautions should we use with statins for women of childbearing age? Chaitany Patel, MD, Lisa Edgerton, PharmD New Hanover Regional Medical Center, Wilmington, North Carolina Donna Flake, MSLS, MSAS Coastal Area Health Education Center, Wilmington, NC EVIDENCE- BASED ANSWER Statins are contraindicated for women who are on its low tissue-penetration properties. pregnant or breastfeeding. Data evaluating statin Cholesterol-lowering with simvastatin 40 mg/d did use for women of childbearing age is limited; how- not disrupt menstrual cycles or effect luteal phase ever, they may be used cautiously with adequate duration (strength of recommendation: C). contraception. Pravastatin may be preferred based CLINICAL COMMENTARY Use statins only as a last resort Before reading this review, I had not been for women of childbearing age ® Dowdenaware Health of the serious Media effects of statin medications I try to follow the USPSTF recommendations and on the developing fetus. In conversations with not screen women aged <45 years without coro- my colleagues, I found that the adverse effects nary artery disease riskCopyright factors for Fhyperlipidemia.or personalof usestatins onlyduring pregnancy are not readily When a woman of any age needs treatment, my known. Such information needs to be more first-line therapy is lifestyle modification. Given the widely disseminated. risks of statin drugs to the developing fetus, Ariel Smits, MD women with childbearing potential should give Department of Family Medicine, Oregon Health & Science fully informed consent and be offered reliable University, Portland contraception before stating statin therapy. I Evidence summary anal, cardiac, tracheal, esophageal, renal, Hydroxymethyl glutaryl coenzyme A and limb deficiency (VACTERL associa- (HMG CoA) reductase inhibitors, com- tion), intrauterine growth retardation monly called statins, have been on the (IUGR), and demise in fetuses exposed market since the late 1980s.
    [Show full text]
  • Prevalence of Drug Interactions in Hospitalized Elderly Patients: a Systematic Review
    Supplementary material Eur J Hosp Pharm Prevalence of drug interactions in hospitalized elderly patients: a systematic review Luciana Mello de Oliveira 1,2; Juliana do Amaral Carneiro Diel1; Alessandra Nunes3; Tatiane da Silva Dal Pizzol 1,2,3 1Programa de Pós-Graduação em Epidemiologia, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul. 2Programa de Pós-Graduação em Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul. 3Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul. Corresponding author: Luciana Mello de Oliveira – [email protected] and Tatiane da Silva Dal Pizzol - [email protected] Supplementary Table 3: Number of patients with interaction, number of DDI per patient with at least one DDI, drugs or drug classes mostly involved with DDI and drug combinations mostly involved with DDI. In cases which prevalence were described, we reported the three drugs mostly involved with drug interactions or the three drug combinations (or drug classes) mostly involved with DDI. ACE: angiotensin-converting enzyme. NA: not available. NSAID: non-steroidal anti-inflammatory drugs. PPI: proton-pump inhibitors. # of patients with # of DDI per patient with First autor interactions interaction Drugs or drug classes mostly involved with DDI Drug combinations mostly involved with DDI Barak-Tsarfir O, et al (61) Unclear: around 56 patients NA NA NA Warfarin; digitoxin; prednisolone antithrombotic agents; non-steroidal anti- 70 (evaluated only serious or inflammatory agents; angiotensin converting enzyme Blix HS, et al (29) contraindicated DDI) NA inhibitors N/A Serious: chlorpromazine + promethazine; chlorpromazine + haloperidol; haloperidol + promethazine; diazepam + phenobarbital; risperidone + haloperidol; carbamazepine + ketoconazole; carbamazepine + chlorpromazine; haloperidol + ketoconazole; chlorpromazine + ketoconazole; chlorpromazine + sodium phosphate.
    [Show full text]
  • An Update on the Efficacy of Anti-Inflammatory Agents for Patients with Schizophrenia: Cambridge.Org/Psm a Meta-Analysis
    Psychological Medicine An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: cambridge.org/psm a meta-analysis 1,2 2,3,4 2,5 6 Review Article N. Çakici , N. J. M. van Beveren , G. Judge-Hundal , M. M. Koola and I. E. C. Sommer5 Cite this article: Çakici N, van Beveren NJM, Judge-Hundal G, Koola MM, Sommer IEC 1Department of Psychiatry and Amsterdam Neuroscience, Academic Medical Center, Meibergdreef 9, 1105 AZ (2019). An update on the efficacy of anti- Amsterdam, the Netherlands; 2Antes Center for Mental Health Care, Albrandswaardsedijk 74, 3172 AA, Poortugaal, inflammatory agents for patients with 3 schizophrenia: a meta-analysis. Psychological the Netherlands; Department of Psychiatry, Erasmus Medical Center, Doctor Molewaterplein 40, 3015 GD 4 Medicine 49, 2307–2319. https://doi.org/ Rotterdam, the Netherlands; Department of Neuroscience, Erasmus Medical Center, Doctor Molewaterplein 40, 5 10.1017/S0033291719001995 3015 GD Rotterdam, the Netherlands; Department of Psychiatry and Biomedical Sciences of Cells and Systems, University Medical Center Groningen, Deusinglaan 2, 9713AW Groningen, the Netherlands and 6Department of Received: 13 February 2019 Psychiatry and Behavioral Sciences, George Washington University School of Medicine and Health Sciences, 2300I Revised: 4 July 2019 St NW, Washington, DC 20052, USA Accepted: 16 July 2019 First published online: 23 August 2019 Abstract Key words: Background. Accumulating evidence shows that a propensity towards a pro-inflammatory Add-on antipsychotic therapy; estrogens; fatty acids; minocycline; N-acetylcysteine status in the brain plays an important role in schizophrenia. Anti-inflammatory drugs might compensate this propensity. This study provides an update regarding the efficacy of Author for correspondence: agents with some anti-inflammatory actions for schizophrenia symptoms tested in rando- N.
    [Show full text]
  • Simvastatin 80Mg Tablets
    Package leaflet: Information for the patient Simvastatin 80mg Tablets Read all of this leaflet carefully before you • if you are due to have an operation. You may need start taking this medicine because it contains to stop taking Simvastatin tablets for a short time important information for you. • if you are Asian, because a different dose may be • Keep this leaflet. You may need to read it again. applicable to you • If you have any further questions, ask your • if you are taking or have taken in the last 7 days doctor or pharmacist. a medicine called fusidic acid (a medicine for bacterial infection) orally or by injection. The • This medicine has been prescribed for you only. combination of fusidic acid and Simvastatin can Do not pass it on to others. It may harm them, lead to serious muscle problems (rhabdomyolysis). even if their signs of illness are the same as yours. Your doctor should do a blood test before you start • If you get any side effects, talk to your doctor taking Simvastatin and if you have any symptoms of or pharmacist. This includes any possible side liver problems while you take Simvastatin. This is to effects not listed in this leaflet. See section 4. check how well your liver is working. What is in this leaflet Your doctor may also want you to have blood tests to check how well your liver is working after you 1 What Simvastatin is and what it is used start taking Simvastatin. for 2 What you need to know before you take While you are on this medicine your doctor will Simvastatin monitor you closely if you have diabetes or are at risk of developing diabetes.
    [Show full text]
  • Drug-Drug Interaction Between Protease Inhibitors and Statins and Proton Pump Inhibitors
    Drug-drug interaction between Protease inhibitors and statins and Proton pump inhibitors Item Type text; Electronic Report Authors Orido, Charles; McKinnon, Samantha Publisher The University of Arizona. Rights Copyright © is held by the author. Download date 01/10/2021 01:48:07 Item License http://rightsstatements.org/vocab/InC/1.0/ Link to Item http://hdl.handle.net/10150/636245 Group 47 :Orido/Samantha 1 Drug-drug interaction between Protease inhibitors and statins and Proton pump inhibitors Course Title: PhPr 862 Date: April 3, 2019 Faculty Advisor: Dr. Dan Malone Students: Charles Orido, Samantha McKinnon Pharm.D. Candidates, Class of 2019 Group 47 :Orido/Samantha 2 Objective The purpose of this article is to provide a systematic review of the pharmacokinetic and clinical data on drug-drug interactions between protease inhibitors (PIs) and statins, atazanavir and proton pump inhibitors (PPIs)and their clinical relevance. Methods A literature search was performed using Medline, EMBASE and google scholar, abstracts from 1970 to 2019 of major conferences were searched and FDA drug information package inserts of the manufacturer of every currently available PI was looked at. All data was summarized and verified by at least two investigators. Results A total of 246 references were identified, 8 of which were studies of pharmacokinetic and pharmacodynamics interactions between simvastatin, lovastatin and protease inhibitors and an additional 7 articles that provided pharmacokinetic of proton pump inhibitors and Atazanavir. Conclusions Protease inhibitors increases the AUC and Cmax of simvastatin by approximately 500% and 517% respectively. Therefore, simvastatin and Lovastatin are not recommended for a co-administration with a protease inhibitor.
    [Show full text]
  • TWYNSTA (Telmisartan/Amlodipine) Tablets Are Indicated for the Treatment of Hypertension, Alone Or with Other Antihypertensive Agents
    HIGHLIGHTS OF PRESCRIBING INFORMATION ---------------------DOSAGE FORMS AND STRENGTHS---------------------- These highlights do not include all the information needed to use • Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg (3) TWYNSTA safely and effectively. See full prescribing information for TWYNSTA. -------------------------------CONTRAINDICATIONS------------------------------ • None TWYNSTA® (telmisartan/amlodipine) Tablets Initial U.S. Approval: 2009 -----------------------WARNINGS AND PRECAUTIONS------------------------ • Avoid fetal or neonatal exposure (5.1) WARNING: AVOID USE IN PREGNANCY • Hypotension: Correct any volume or salt depletion before initiating See full prescribing information for complete boxed warning. therapy. Observe for signs and symptoms of hypotension. (5.2) When pregnancy is detected, discontinue TWYNSTA as soon as possible. • Titrate slowly in patients with hepatic (5.4) or severe renal impairment Drugs that act directly on the renin-angiotensin system can cause injury (5.5) and even death to the developing fetus (5.1) • Heart failure: Monitor for worsening (5.8) • Avoid concomitant use of an ACE inhibitor and angiotensin receptor ----------------------------INDICATIONS AND USAGE--------------------------- blocker (5.6) • TWYNSTA is an angiotensin II receptor blocker (ARB) and a • Myocardial infarction: Uncommonly, initiating a CCB in patients with dihydropyridine calcium channel blocker (DHP-CCB) combination severe obstructive coronary artery disease may precipitate myocardial product indicated for the treatment
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Importance of Hepatic Transporters, Including Basolateral Efflux Proteins, in Drug Disposition: Impact of Phospholipidosis and Non-Alcoholic Steatohepatitis
    IMPORTANCE OF HEPATIC TRANSPORTERS, INCLUDING BASOLATERAL EFFLUX PROTEINS, IN DRUG DISPOSITION: IMPACT OF PHOSPHOLIPIDOSIS AND NON-ALCOHOLIC STEATOHEPATITIS Brian C. Ferslew A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmaceutical Sciences in the UNC Eshelman School of Pharmacy Chapel Hill 2014 Approved by: Dhiren Thakker Mary F. Paine A. Sidney Barritt Kim L.R. Brouwer Jo Ellen Rodgers Wei Jia ©2014 Brian C. Ferslew ALL RIGHTS RESERVED ii ABSTRACT Brian C. Ferslew: Importance of Hepatic Transporters, Including Basolateral Efflux Proteins, in Drug Disposition: Impact of Phospholipidosis and Non-Alcoholic Steatohepatitis (Under the direction of Kim L.R. Brouwer) The objective of this dissertation project was to develop preclinical and clinical tools to assess the impact of liver pathology on transporter-mediated systemic and hepatic exposure to medications. A translational approach utilizing established pre-clinical hepatic transport systems, mathematical modeling, and a pivotal in vivo human study was employed. A novel application of rat sandwich-cultured hepatocytes (SCH) was developed to evaluate the impact of drug-induced phospholipidosis on the vectorial transport of probe substrates for hepatic basolateral and canalicular transport proteins. Results indicated that rat SCH treated with prototypical hepatic phospholipidosis inducers are a sensitive and selective model for drug-induced phospholipidosis; both organic anion transporting polypeptide-mediated uptake and bile salt export pump-mediated biliary excretion were reduced after the onset of phospholipidosis. Enalapril currently is being investigated for its anti-fibrotic effects in the treatment of patients with non-alcoholic steatohepatitis (NASH).
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]